Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Protagonist Therapeutics exercised its opt-out right for rusfertide with partner Takeda, triggering an immediate $200M payment eligibility and shifting U.S. rights exclusively to Takeda. The move secures up to $475M in cash tied to the opt-out and potential FDA approval, plus tiered royalties of 14-29% on worldwide sales.
Key figures
- Drug Name
- rusfertide
- Deal Value Usd
- 475000000
- Approval milestone
- 75000000
- Regulatory milestone
- 200000000
- Upfront opt out payment
- 200000000
- Royalty range low percent
- 14
- Royalty range high percent
- 29
- Total potential milestones
- 975000000
- Weighted avg royalty percent
- 21
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.